Herpesvirus in Idiopathic Pulmonary Fibrosis
|Study Design:||Time Perspective: Prospective|
|Official Title:||Herpesvirus in Idiopathic Pulmonary Fibrosis|
- Viral load [ Time Frame: 1 year ] [ Designated as safety issue: No ]EBV viral load in induced sputum collected at each clinic visit over a one year period
- Viral load [ Time Frame: 1 year ] [ Designated as safety issue: No ]EBV viral load in saliva collected every clinic visit over a one year period
- Viral load [ Time Frame: one time point ] [ Designated as safety issue: No ]EBV viral load in lung tissue collected at the tim e of lung transplantation
Biospecimen Retention: Samples Without DNA
|Study Start Date:||July 2005|
|Study Completion Date:||August 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
Controls - Clinic
Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
IPF patient undergoing lung transplant
Lung tissue from organ donor
IPF is a progressive disease where there is no proven treatment, other than lung transplant. Doctors do not know what causes IPF. We think that IPF is caused by a viral infection, particularly herpes virus. The goal of this experiment is to build the case for a causal link between IPF and herpes virus. This information is important to help us develop new therapies to treat patients with IPF.
We will collect lung tissue at the time of lung transplant surgery from IPF patients and from organ donors as controls. Control lung tissue was collected if it was removed as a part of regular care or would otherwise be discarded. No extra tissue was taken solely for this research project.
We will also perform a prospective longitudinal study on IPF patients and their household partners. IPF subjects are included if they have no other pulmonary disease and the diagnosis of IPF is confirmed by lung biopsy or by clinical and chest CT findings. The control group will consist of subjects without respiratory symptoms or pulmonary diseases who are the household partner or spouse of an enrolled IPF subject and who accompanies the IPF patient to outpatient clinic visits. If there is no household partner, or if the partner is unwilling to participate, we will still enroll the IPF subject who qualifies for the study and is willing to participate. Saliva, induced sputum, and venous blood will be collected from IPF and control subjects after informed consent at each clinic visit. Visits usually are at approximately 3-4 month intervals over a one year period.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00228670
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Arlene Stecenko, MD||Emory University|